title: Current misunderstandings in the management of ulcerative colitis.
abstract: Past and ongoing therapeutic concepts for ulcerative colitis have only been moderately successful. A significant proportion of patients with ulcerative colitis will still have to undergo colectomy and overall half of the patients do not achieve sustained remission, leading to impairment of physical and mental health, social life, employment issues and sexual activity. Reluctance to treat patients early on with sufficiently potent drug regimens is obvious. Several popular misconceptions might have led to this situation. First, ulcerative colitis is still considered a more 'benign' disease than Crohn's disease. Furthermore, the general assumption is often that colectomy can 'cure' the disease. Mucosal healing as a therapeutic target has not been widely accepted. Finally, the use of antitumour necrosis factor antibodies in ulcerative colitis has been low because this treatment is considered to be less effective than in Crohn's disease. In the current review we try to disprove these misunderstandings by discussing relevant studies showing how harmful this disease can be and explaining why future studies targeting sustained suppression of inflammation could have an enormous impact on the natural course of the disease. Until these studies are available, we encourage physicians to intensify and maintain treatment until sustained remission and mucosal healing has been reached.
authors.affiliation: Department of Gastroenterology, Academic Medical Centre, Meibergdreef 9-C2-112, 1105 AZ Amsterdam, The Netherlands.
authors.forename: Thomas
authors.initials: T
authors.lastname: Ochsenkühn
authors.forename: Geert
authors.initials: G
authors.lastname: D'Haens
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D003082:Colectomy / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000628:therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000502:physiology; D019449:Pouchitis / Q000209:etiology; D011379:Prognosis; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab